Bioras Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 11-12-2024
- Paid Up Capital ₹ 0.30 M
as on 11-12-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
About Bioras Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Shesheer Munpally, Rachana Tripathi, and Sreeman Mamidyala serve as directors at the Company.
- CIN/LLPIN
U24239TG2021PTC153970
- Company No.
153970
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bioras Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sreeman Mamidyala  | Director | 17-Jan-2022 | Current |
| Shesheer Munpally | Director | 10-Aug-2021 | Current |
| Rachana Tripathi | Director | 10-Aug-2021 | Current |
Financial Performance of Bioras Pharma.
Bioras Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Bioras Pharma?
In 2022, Bioras Pharma had a public holding of 66.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Huwel Lifesciences Private LimitedActive 9 years 10 monthsShesheer Munpally and Rachana Tripathi are mutual person
Hlss Manufacturing Private LimitedActive 3 years 6 monthsShesheer Munpally and Rachana Tripathi are mutual person
- Hlabs Private LimitedActive 2 years 6 months
Shesheer Munpally and Rachana Tripathi are mutual person
- Bhubaneswar City Knowledge Innovation Cluster FoundationActive 2 years 10 months
Shesheer Munpally is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioras Pharma?
Bioras Pharma has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioras Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioras Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
